Covid_19. Corona virus infection, unspecified
Conditions
Interventions
Intervention group: Patients who continue to have low oxygen saturation despite receiving antiviral drugs and corticosteroids receive tocilizumab. The drug tocilizumab made in China is Roche brand, wh
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Positive PCR test for COVID- 19 Oxygen saturation less than 90% Hospitalized with pneumonia High levels of interleukin 6 Not participating in another study
Exclusion criteria
Exclusion criteria: Pregnant or lactating women Severe liver disease (liver enzymes more than 5 times normal) Allergic reaction to the used drugs Neutrophils less than 500 Platelets less than 50000 Intestinal diverticulosis or intestinal perforation Positive viral markers or positive tuberculosis skin test
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality rate. Timepoint: End of study. Method of measurement: Patient file. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalized in the intensive care unit. Timepoint: End of study. Method of measurement: Patient file.;Number of days hospitalized in the intensive care unit. Timepoint: End of study. Method of measurement: Patient file.;Interleukin 6. Timepoint: Before and after the intervention. Method of measurement: Measuring kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRooh Angiz Nashibi
Ahvaz University of Medical Sciences
Outcome results
None listed